Norepinephrine Bitartrate

First-quarter sales from continuing operations of $3.59 billion increased 2% on a reported basis and 3% on a constant currency basis, exceeding the company’s previously issued guidance1 First-quarter U.S. GAAP2 diluted earnings per share (EPS) from continuing operations were $0.07 and adjusted diluted EPS from continuing operations were $0.65, exceeding the company’s previously issued guidance Baxter now expects full-year 2024 sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis Baxter now expects full-year adjusted EPS of $2.88 to $2.981 Recent U.S. FDA clearance of Novum IQ large volume infusion pump and Dose IQ Safety Software advances connected and intelligent infusion therapy portfolio DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International, Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024. “Baxter’s results in the first quarter reflect the company’s solid operational performance, fueled by the benefits being realized from our ongoing strategic transformation initiatives, including our new operating model structure, and continued strong execution across our integrated supply chain network,” said José (Joe) E. Almeida, chair, president and chief executive officer. “We are squarely focused on improving our operational execution and excited by the opportunities we are creating through recent innovation milestones. Our objective remains to accelerate performance and drive increased value for patients, healthcare providers and shareholders.” First-Quarter Financial Results Worldwide sales from continuing operations in the first quarter totaled $3.59 billion, an increase of 2% on a reported basis and 3% on a constant currency basis, exceeding the company’s previously issued guidance of approximately 1% on a reported basis and 1% to 2% on a constant currency basis. Continuing operations exclude Baxter’s BioPharma Solutions (BPS) business, which was divested at the end of the third quarter of 2023. U.S. sales from continuing operations in the first quarter totaled $1.66 billion, flat year-over-year on a reported basis. International sales from continuing operations totaled $1.93 billion, an increase of 5% on both a reported basis and at constant currency rates. First-quarter sales performance was driven by better-than-expected results across the majority of Baxter’s business segments. Sales performance by segment was led by double-digit growth in Pharmaceuticals, reflecting the impact of new product launches and increased demand for Baxter’s Drug Compounding services. Baxter’s Medical Products & Therapies and Kidney Care segments both delivered mid-single-digit growth at constant currency rates, reflecting the benefit of positive demand and pricing across these two segments. This strong growth helped offset a high single-digit decline in Baxter’s Healthcare Systems & Technologies segment, reflecting the phasing of certain orders to later in the year, timing of backlog reduction efforts in the prior year period and softness in the U.S. primary care market, as well as some operational challenges that are being addressed to enhance the future performance of this segment. Growth for the Healthcare Systems & Technologies segment is expected to meaningfully improve in the second half of the year. Please see the attached schedules accompanying this press release for additional details on sales performance in the quarter, including breakouts by Baxter’s segments. For the first quarter, total net income attributable to Baxter on a U.S. GAAP basis was $37 million, or $0.07 per diluted share. Total U.S. GAAP diluted EPS includes $0.07 from continuing operations. These results include special items totaling $294 million, primarily related to the impact of intangible amortization, separation-related costs and business optimization costs, among other factors. On an adjusted basis, excluding the impact of special items, income from continuing operations was $0.65 per diluted share, which exceeded the company’s previously issued guidance of $0.59 to $0.62 per diluted share, driven by top-line performance and operational execution across Integrated Supply Chain. Recent Highlights3 Baxter continues to advance key strategic priorities in pursuit of its Mission to Save and Sustain Lives. Among recent highlights, the company: Announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform – which includes Baxter’s syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite – integrates the user experience across its LVP and SYR pumps and helps to reduce the burden of non-critical tasks so that nurses, pharmacists and other clinicians can spend more time focused on patient care. The Novum IQ LVP and Novum IQ SYR are available to order in the U.S. Announced the continued expansion of its Pharmaceuticals portfolio with five injectable launches in the U.S. that reinforce the company’s focus on differentiated products and address unmet patient needs in key therapeutic areas. These launches include: Norepinephrine Bitartrate in 5% Dextrose Injection in a new 16 mg/250 mL strength Vasopressin in 0.9% Sodium Chloride Injection, the first and only FDA-approved ready-to-use Vasopressin in a flexible container Vancomycin Injection, USP in 5% Dextrose in new 1.25 g/250 mL and 1.5 g/300 mL strengths Ropivacaine Hydrochloride Injection, USP in a ready-to-use, single-dose infusion bag Regadenoson Injection in a pre-filled syringe Kidney Care Separation Update Baxter’s preparations continue for the proposed separation of its Kidney Care segment. As announced on March 4, 2024, the company is exploring a potential sale of the Kidney Care business in lieu of a proposed spinoff of that business. No final decision on the separation structure has been made. Regardless of the selected path, Baxter currently expects the separation of its Kidney Care business to take place in the second half of 2024. 2024 Financial Outlook For full-year 2024: Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis. The company expects adjusted earnings, before special items, of $2.88 to $2.98 per diluted share. For second-quarter 2024: The company expects sales growth of approximately 1% on a reported basis and 2% to 3% on a constant currency basis. The company expects adjusted earnings, before special items, of $0.65 to $0.67 per diluted share. A webcast of Baxter’s first-quarter 2024 conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at beginning at 7:30 a.m. CDT on May 2, 2024. Please see for more information regarding this and future investor events and webcasts. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit and follow us on X/Twitter, LinkedIn and Facebook. Non-GAAP Financial Measures Non-GAAP financial measures may enhance an understanding of the company’s operations and may facilitate an analysis of those operations, particularly in evaluating performance from one period to another. Management believes that non-GAAP financial measures, when used in conjunction with the results presented in accordance with U.S. GAAP and the company’s reconciliations to corresponding U.S. GAAP financial measures (which are included in the tables accompanying this release), may enhance an investor’s overall understanding of the company’s past financial performance and prospects for the future. Management uses these non-GAAP measures internally in financial planning, to monitor business unit performance, and, in some cases, for purposes of determining incentive compensation. This information should be considered in addition to, and not as substitutes for, information prepared in accordance with U.S. GAAP. Net sales growth on a constant currency basis is a non-GAAP financial measure that provides information on the percentage change in net sales growth as if foreign currency exchange rates had remained constant between the prior and current periods. Other non-GAAP financial measures included in this release and the accompanying tables (including within the tables that provide the company’s detailed reconciliations to the corresponding U.S. GAAP financial measures) are: adjusted gross margin, adjusted selling, general, and administrative expenses, adjusted research and development expenses, adjusted other operating expense (income), net, adjusted operating income (loss), adjusted other income (expense), net, adjusted income (loss) from continuing operations before income taxes, adjusted income tax expense (benefit), adjusted income (loss) from continuing operations, adjusted income (loss) from discontinued operations, adjusted net income (loss), adjusted net income (loss) attributable to Baxter stockholders, adjusted diluted earnings per share from continuing operations, adjusted diluted earnings per share from discontinued operations and adjusted diluted earnings per share. Those non-GAAP financial measures exclude the impact of special items. For the quarters ended March 31, 2024 and 2023, special items for one or more periods included intangible asset amortization, business optimization charges, acquisition and integration costs, separation-related costs, expenses related to European medical devices regulation, and certain tax matters. These items are excluded because they are highly variable or unusual and of a size that may substantially impact the company’s reported operations for a period. Additionally, intangible asset amortization is excluded as a special item to facilitate an evaluation of current and past operating performance and is consistent with how management and the company’s Board of Directors assess performance. This release and the accompanying tables also include free cash flow, a non-GAAP financial measure that Baxter defines as operating cash flow less capital expenditures. Free cash flow is used by management and the company’s Board of Directors to evaluate the cash generated from Baxter’s operating activities each period after deducting its capital spending. This release also includes forecasts of certain of the aforementioned non-GAAP measures on a forward-looking basis as part of the company’s financial outlook for upcoming periods. Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking adjusted diluted EPS guidance excludes potential charges or gains that would be reflected as non-GAAP adjustments to earnings. Baxter provides forward-looking adjusted diluted EPS guidance because it believes that this measure provides useful information for the reasons noted above. Baxter has not provided reconciliations of forward-looking adjusted EPS guidance to forward-looking GAAP EPS guidance because the company is unable to predict with reasonable certainty the impact of legal proceedings, future business optimization actions, separation-related costs, integration-related costs, asset impairments and unusual gains and losses, and the related amounts are unavailable without unreasonable efforts (as specified in the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K). In addition, Baxter believes that such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance. Forward-Looking Statements This release includes forward-looking statements concerning the company’s financial results (including the outlook for second-quarter and full-year 2024) and business development and regulatory activities. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company’s ability to execute and complete strategic initiatives, asset dispositions and other transactions and development activities, including the proposed separation of the company’s Kidney Care business, the company’s plans to simplify its manufacturing footprint and the timing for such transactions, the ability to satisfy any applicable conditions and the expected proceeds, consideration and benefits; failure to accurately forecast or achieve the company’s short- and long-term financial performance and goals (including with respect to the company’s strategic initiatives and other actions) and related impacts on our liquidity; the company’s ability to execute on its capital allocation plans, including the company’s debt repayment plans, the timing and amount of any dividends, share repurchases and divestiture proceeds and, if the company proceeds with the separation of the Kidney Care business in the form of a spinoff, the capital structure of the public company that would be formed (and the resulting capital structure for the remaining company); the company’s ability to successfully integrate acquisitions; the impact of global economic conditions (including, among other things, inflation levels, interest rates, financial market volatility, banking crises, the potential for a recession, the war in Ukraine, the conflict in the Middle East (including attacks on merchant ships in the Red Sea), tensions amongst China, Taiwan and the U.S., and the potential for escalation of these conflicts, the related economic sanctions being imposed globally in response to the conflicts and potential trade wars and global public health crises, pandemics and epidemics, such as the COVID-19 pandemic, or the anticipation of any of the foregoing, on the company’s operations and on the company’s employees, customers, suppliers, and foreign governments in countries in which the company operates; downgrades to the company’s credit ratings or ratings outlooks, and the impact on the company’s funding costs and liquidity; product development risks, including satisfactory clinical performance and obtaining and maintaining required regulatory approvals (including as a result of evolving regulatory requirements or the withdrawal or resubmission of any pending applications), the ability to manufacture at appropriate scale and the general unpredictability associated with the product development cycle; product quality or patient safety issues leading to product recalls, withdrawals, launch delays, warning letters, import bans, sanctions, seizures, litigation or declining sales, including the focus on evaluating product portfolios for the potential presence or formation of nitrosamines; future actions of, or failures to act or delays in acting by, FDA, the European Medicines Agency or any other regulatory body or government authority (including the SEC, Department of Justice or the Attorney General of any State) that could delay, limit or suspend product development, manufacturing or sale or result in seizures, recalls, injunctions, monetary sanctions or criminal or civil liabilities; demand and market acceptance risks for, and competitive pressures related to, new and existing products, challenges with the company’s ability to accurately predict changing consumer preferences and future expenditures and inventory levels, and challenges with the company’s ability to monetize new and existing products and services, the impact of those products on quality and patient safety concerns and the need for ongoing training and support for our products; breaches, including by cyber-attack, data leakage, unauthorized access or theft, or failures of or vulnerabilities in, the company’s information technology systems or products; the continuity, availability and pricing of acceptable raw materials and component parts, the company’s ability to pass some or all of these costs to the company’s customers through recent price increases or otherwise, and the related continuity of the company’s manufacturing and distribution and those of the company’s suppliers; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing, sterilization or supply difficulties, including as a result of natural disaster, war, terrorism, global public health crises and epidemics/pandemics, regulatory actions or otherwise; the company’s ability to finance and develop new products or enhancements on commercially acceptable terms or at all; loss of key employees, the occurrence of labor disruptions (including as a result of labor disagreements under bargaining agreements or national trade union agreements or disputes with works councils) or the inability to attract, develop, retain and engage employees; failures with respect to the company’s quality, compliance or ethics programs; future actions of third parties, including third-party payers and the company’s customers and distributors (including GPOs and IDNs); changes to legislation and regulation and other governmental pressures in United States and globally, including the cost of compliance and potential penalties for purported noncompliance thereof, including new or amended laws, rules and regulations as well as the impact of healthcare reform and its implementation, suspension, repeal, replacement, amendment, modification and other similar actions undertaken by the United States or foreign governments, including with respect to pricing, reimbursement, taxation and rebate policies; the outcome of pending or future litigation; the impact of competitive products and pricing, including generic competition, drug reimportation and disruptive technologies; global regulatory, trade and tax policies, including with respect to climate change and other sustainability matters; the ability to protect or enforce the company’s patents or other proprietary rights (including trademarks, copyrights, trade secrets and know-how) or where the patents of third parties prevent or restrict the company’s manufacture, sale or use of affected products or technology; the impact of any goodwill, intangible asset or other long-lived asset impairments on the company’s operating results; fluctuations in foreign exchange and interest rates; any changes in law concerning the taxation of income (whether with respect to current or future tax reform); actions by tax authorities in connection with ongoing tax audits; and other risks identified in Baxter’s most recent filings on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements unless otherwise required by the federal securities laws. Baxter, Dose IQ, IQ Enterprise and Novum IQ are trademarks of Baxter International Inc. Any other trademarks or product brands appearing herein are the property of their respective owners. ________________________________ 1 Sales growth at constant currency rates and adjusted diluted EPS, as well as forecasts of those items on a forward-looking basis, are non-GAAP financial measures. See the “Non-GAAP Financial Measures” section below for information about the non-GAAP financial measures included in this release and see the accompanying tables to this press release for reconciliations of those non-GAAP measures to the corresponding U.S. GAAP measures. 2 Generally Accepted Accounting Principles 3 See links to original press releases for additional product information. BAXTER INTERNATIONAL INC. Consolidated Statements of Income (unaudited) (in millions, except per share and percentage data) Three Months Ended March 31, 2024 2023 Change NET SALES $ 3,592 $ 3,513 2% COST OF SALES 2,205 2,238 (1)% GROSS MARGIN 1,387 1,275 9% % of Net Sales 38.6 % 36.3 % 2.3 pts SELLING, GENERAL AND ADMINISTRATIVE EXPENSES 1,027 995 3% % of Net Sales 28.6 % 28.3 % 0.3 pts RESEARCH AND DEVELOPMENT EXPENSES 176 164 7% % of Net Sales 4.9 % 4.7 % 0.2 pts OTHER OPERATING INCOME, NET (3 ) (13 ) (77)% OPERATING INCOME 187 129 45% % of Net Sales 5.2 % 3.7 % 1.5 pts INTEREST EXPENSE, NET 78 117 (33)% OTHER INCOME, NET (7 ) (2 ) NM INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES 116 14 NM INCOME TAX BENEFIT 77 14 NM % of Income from Continuing Operations Before Income Taxes 66.4 % 100.0 % (33.6) pts INCOME FROM CONTINUING OPERATIONS 39 — NM INCOME FROM DISCONTINUED OPERATIONS, NET OF TAX — 45 (100)% NET INCOME 39 45 (13)% NET INCOME ATTRIBUTABLE TO NONCONTROLLING INTERESTS 2 1 100% NET INCOME ATTRIBUTABLE TO BAXTER STOCKHOLDERS $ 37 $ 44 (16)% INCOME FROM CONTINUING OPERATIONS PER COMMON SHARE Basic $ 0.07 $ 0.00 NM Diluted $ 0.07 $ 0.00 NM INCOME FROM DISCONTINUED OPERATIONS PER COMMON SHARE Basic $ 0.00 $ 0.09 (100)% Diluted $ 0.00 $ 0.09 (100)% NET INCOME PER COMMON SHARE Basic $ 0.07 $ 0.09 (22)% Diluted $ 0.07 $ 0.09 (22)% WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING Basic 508 505 Diluted 510 505 ADJUSTED OPERATING INCOME (excluding special items)¹ $ 515 $ 439 17% ADJUSTED INCOME FROM CONTINUING OPERATIONS (excluding special items)¹ $ 333 $ 249 34% ADJUSTED INCOME FROM DISCONTINUED OPERATIONS (excluding special items)1 $ — $ 49 (100)% ADJUSTED NET INCOME ATTRIBUTABLE TO BAXTER STOCKHOLDERS (excluding special items)¹ $ 331 $ 297 11% ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS (excluding special items)¹ $ 0.65 $ 0.49 33% ADJUSTED DILUTED EPS FROM DISCONTINUED OPERATIONS (excluding special items)¹ $ 0.00 $ 0.10 (100)% ADJUSTED DILUTED EPS (excluding special items)¹ $ 0.65 $ 0.59 10% 1Refer to page 9 for a description of the adjustments and a reconciliation to U.S. GAAP measures. NM - Not Meaningful BAXTER INTERNATIONAL INC. Description of Adjustments and Reconciliation of U.S. GAAP to Non-GAAP Measures (unaudited, in millions) The company’s U.S. GAAP results for the three months ended March 31, 2024 included special items which impacted the U.S. GAAP measures as follows: Gross Margin Selling, General and Administrative Expenses Research and Development Expenses Operating Income Income From Continuing Operations Before Income Taxes Income Tax Expense (Benefit) Income From Continuing Operations Net Income Net Income Attributable to Baxter Stockholders Diluted Earnings Per Share from Continuing Operations Diluted Earnings Per Share Reported $ 1,387 $ 1,027 $ 176 $ 187 $ 116 $ 77 $ 39 $ 39 $ 37 $ 0.07 $ 0.07 Reported percent of net sales (or effective tax rate for income tax expense) 38.6 % 28.6 % 4.9 % 5.2 % 3.2 % 66.4 % 1.1 % 1.1 % 1.0 % Intangible asset amortization 114 (52 ) — 166 166 40 126 126 126 0.25 0.25 Business optimization items1 14 (27 ) (16 ) 57 57 15 42 42 42 0.08 0.08 Acquisition and integration items2 1 (4 ) — 5 5 1 4 4 4 0.01 0.01 Separation-related costs3 4 (88 ) — 92 92 13 79 79 79 0.15 0.15 European medical devices regulation4 8 — — 8 8 2 6 6 6 0.01 0.01 Tax matters5 — — — — — (37 ) 37 37 37 0.07 0.07 Adjusted $ 1,528 $ 856 $ 160 $ 515 $ 444 $ 111 $ 333 $ 333 $ 331 $ 0.65 $ 0.65 Adjusted percent of net sales (or effective tax rate for income tax expense) 42.5 % 23.8 % 4.5 % 14.3 % 12.4 % 25.0 % 9.3 % 9.3 % 9.2 % Reported Adjusted Net income $ 39 $ 333 Less: Net income attributable to noncontrolling interests 2 2 Net income attributable to Baxter stockholders $ 37 $ 331 The company’s U.S. GAAP results for the three months ended March 31, 2023 included special items which impacted the U.S. GAAP measures as follows: Gross Margin Selling, General and Administrative Expenses Research and Development Expenses Other Operating Income, Net Operating Income Income From Continuing Operations Before Income Taxes Income Tax Expense (Benefit) Income From Continuing Operations Income From Discontinued Operations Net Income Net Income Attributable to Baxter Stockholders Diluted Earnings Per Share from Continuing Operations Diluted Earnings Per Share from Discontinued Operations Diluted Earnings Per Share Reported $ 1,275 $ 995 $ 164 $ (13 ) $ 129 $ 14 $ 14 $ — $ 45 $ 45 $ 44 $ 0.00 $ 0.09 $ 0.09 Reported percent of net sales (or effective tax rate for income tax expense) 36.3 % 28.3 % 4.7 % (0.4 )% 3.7 % 0.4 % 100.0 % 0.0 % 1.3 % 1.3 % 1.3 % Intangible asset amortization 110 (52 ) — — 162 162 36 126 — 126 126 0.25 0.00 0.25 Business optimization items1 35 (92 ) (7 ) — 134 134 27 107 — 107 107 0.21 0.00 0.21 Acquisition and integration items2 — (6 ) — 13 (7 ) (7 ) (2 ) (5 ) — (5 ) (5 ) (0.01 ) 0.00 (0.01 ) Separation-related costs3 1 (8 ) — — 9 9 — 9 7 16 16 0.02 0.01 0.03 European medical devices regulation4 12 — — — 12 12 3 9 — 9 9 0.02 0.00 0.02 Tax matters5 — — — — — — (3 ) 3 (3 ) — — 0.01 (0.01 ) 0.00 Adjusted $ 1,433 $ 837 $ 157 $ — $ 439 $ 324 $ 75 $ 249 $ 49 $ 298 $ 297 $ 0.49 $ 0.10 $ 0.59 Adjusted percent of net sales (or effective tax rate for income tax expense) 40.8 % 23.8 % 4.5 % 0.0 % 12.5 % 9.2 % 23.1 % 7.1 % 1.4 % 8.5 % 8.5 % Reported Adjusted Income (loss) from continuing operations $ — $ 249 Less: Net income attributable to noncontrolling interests 1 1 Income (loss) from continuing operations attributable to Baxter stockholders $ (1 ) $ 248 Weighted-average diluted shares as reported 505 Effect of dilutive securities that were anti-dilutive to dilutive EPS as reported 2 Weighted-average diluted shares as adjusted 507 1 The company’s results in 2024 and 2023 included costs related to programs to optimize its organization and cost structure. In 2024, these costs primarily related to a program to centralize certain of its research and development activities into a new location and, to a lesser extent, the implementation of a new operating model intended to streamline and simplify its operations. In 2023, these costs primarily related to the implementation of its new operating model. 2 The company’s results in 2024 and 2023 included acquisition and integration-related items comprised of Hillrom acquisition and integration expenses. In 2023 those costs are offset by net gains from changes in the fair value of contingent consideration liabilities. 3 The company's results in 2024 and 2023 included separation-related costs primarily related to external advisors supporting its activities to prepare for the proposed separation of its Kidney Care segment, which are reported in continuing operations. The company's results in 2023 also included separation-related costs related to the sale of its BioPharma Solutions (BPS) business, which are reported in discontinued operations. 4 The company’s results in 2024 and 2023 included incremental costs to comply with the European Union’s medical device regulations for previously registered products, which primarily consist of contractor costs and other direct third-party costs. The company considers the adoption of these regulations to be a significant one-time regulatory change and believes that the costs of initial compliance for previously registered products over the implementation period are not indicative of its core operating results. 5 The company’s results in 2024 included income tax expenses resulting from internal reorganization transactions related to the proposed separation of its Kidney Care segment. The company’s results in 2023 included a reallocation of income tax expense between discontinued operations and continuing operations resulting from the application of intraperiod tax allocation to its adjusted results in an interim period. For more information on the company's use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. BAXTER INTERNATIONAL INC. Sales by Operating Segment (unaudited) ($ in millions) The Medical Products and Therapies segment includes sales of our sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of our connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies, precision positioning devices and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding. The Kidney Care segment includes sales of chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies (CRRT) and other organ support therapies. Other sales not allocated to a segment primarily include sales of products and services provided directly through certain of our manufacturing facilities. Three Months Ended March 31, % Growth @ Actual Rates % Growth @ Constant Rates 2024 2023 Infusion Therapies and Technologies $ 966 $ 911 6 % 6 % Advanced Surgery 263 246 7 % 8 % Medical Products and Therapies 1,229 1,157 6 % 6 % Care and Connectivity Solutions 402 429 (6 )% (7 )% Front Line Care 265 302 (12 )% (12 )% Healthcare Systems and Technologies 667 731 (9 )% (9 )% Injectables and Anesthesia 328 305 8 % 8 % Drug Compounding 250 218 15 % 15 % Pharmaceuticals 578 523 11 % 11 % Chronic Therapies 888 884 0 % 2 % Acute Therapies 214 188 14 % 15 % Kidney Care 1,102 1,072 3 % 4 % Other 16 30 (47 )% (47 )% Total - Continuing Operations $ 3,592 $ 3,513 2 % 3 % In connection with our segment change in the third quarter of 2023, we reclassified $8 million of sales from the first quarter of 2023 from Chronic Therapies to Acute Therapies to conform to the current period presentation. Additionally, in connection with the reclassification of our BPS business to discontinued operations during the second quarter of 2023, we reclassified $2 million of contract manufacturing revenues from the first quarter of 2023 from BPS to Other (within continuing operations), as the related manufacturing facility was not part of that divestiture transaction. Constant currency growth is a non-GAAP measure. For more information on the company’s use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. BAXTER INTERNATIONAL INC. Segment Operating Income (unaudited) ($ in millions) Three Months Ended March 31, 2024 2023 Medical Products and Therapies $ 227 $ 197 % of Segment Net Sales 18.5 % 17.0 % Healthcare Systems and Technologies 67 112 % of Segment Net Sales 10.0 % 15.3 % Pharmaceuticals 78 87 % of Segment Net Sales 13.5 % 16.6 % Kidney Care 159 57 % of Segment Net Sales 14.4 % 5.3 % Other 4 7 Total 535 460 Unallocated corporate costs (20 ) (21 ) Intangible asset amortization expense (166 ) (162 ) Business optimization items (57 ) (134 ) Acquisition and integration items (5 ) 7 Divestiture-related costs (92 ) (9 ) European Medical Devices Regulation (8 ) (12 ) Total operating income 187 129 Interest expense, net 78 117 Other income, net (7 ) (2 ) Income from continuing operations before income taxes $ 116 $ 14 BAXTER INTERNATIONAL INC. Operating Segment Sales by U.S. and International (unaudited) ($ in millions) Three Months Ended March 31, 2024 2023 % Growth U.S. International Total U.S. International Total U.S. International Total Infusion Therapies and Technologies $ 526 $ 440 $ 966 $ 514 $ 397 $ 911 2 % 11 % 6 % Advanced Surgery 147 116 263 144 102 246 2 % 14 % 7 % Medical Products and Therapies 673 556 1,229 658 499 1,157 2 % 11 % 6 % Care and Connectivity Solutions 278 124 402 298 131 429 (7 )% (5 )% (6 )% Front Line Care 195 70 265 221 81 302 (12 )% (14 )% (12 )% Healthcare Systems and Technologies 473 194 667 519 212 731 (9 )% (8 )% (9 )% Injectables and Anesthesia 191 137 328 173 132 305 10 % 4 % 8 % Drug Compounding — 250 250 — 218 218 0 % 15 % 15 % Pharmaceuticals 191 387 578 173 350 523 10 % 11 % 11 % Chronic Therapies 226 662 888 229 655 884 (1 )% 1 % 0 % Acute Therapies 85 129 214 64 124 188 33 % 4 % 14 % Kidney Care 311 791 1,102 293 779 1,072 6 % 2 % 3 % Other 11 5 16 24 6 30 (54 )% (17 )% (47 )% Total - Continuing Operations $ 1,659 $ 1,933 $ 3,592 $ 1,667 $ 1,846 $ 3,513 (0 )% 5 % 2 % BAXTER INTERNATIONAL INC. Reconciliation of Non-GAAP Financial Measure Operating Cash Flow to Free Cash Flow (unaudited) ($ in millions) Three Months Ended March 31, 2024 2023 Cash flows from operations – continuing operations $ 163 $ 469 Cash flows from investing activities - continuing operations (166 ) (163 ) Cash flows from financing activities - continuing operations (140 ) (372 ) Cash flows from operations - continuing operations $ 163 $ 469 Capital expenditures - continuing operations (176 ) (165 ) Free cash flow - continuing operations $ (13 ) $ 304 Three Months Ended March 31, 2024 2023 Cash flows from operations – discontinued operations $ — 10 Cash flows from investing activities - discontinued operations — (7 ) Cash flows from operations - discontinued operations $ — $ 10 Capital expenditures - discontinued operations — (7 ) Free cash flow - discontinued operations $ — $ 3 Three Months Ended March 31, 2024 2023 Cash flows from operations – Total Baxter $ 163 $ 479 Cash flows from investing activities - Total Baxter (166 ) (170 ) Cash flows from financing activities - Total Baxter (140 ) (372 ) Cash flows from operations - Total Baxter $ 163 $ 479 Capital expenditures - Total Baxter (176 ) (172 ) Free cash flow - Total Baxter $ (13 ) $ 307 Free cash flow is a non-GAAP measure. For more information on the company’s use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. BAXTER INTERNATIONAL INC. Reconciliation of Non-GAAP Financial Measure Change in Net Sales Growth As Reported to Constant Currency Sales Growth From the Three Months Ended March 31, 2023 to the Three Months Ended March 31, 2024 (unaudited) Net Sales Growth As Reported FX Constant Currency Sales Growth* Infusion Therapies and Technologies 6 % 0 % 6 % Advanced Surgery 7 % 1 % 8 % Medical Products and Therapies 6 % 0 % 6 % Care and Connectivity Solutions (6 )% (1 )% (7 )% Front Line Care (12 )% 0 % (12 )% Healthcare Systems and Technologies (9 )% 0 % (9 )% Injectables and Anesthesia 8 % 0 % 8 % Drug Compounding 15 % 0 % 15 % Pharmaceuticals 11 % 0 % 11 % Chronic Therapies 0 % 2 % 2 % Acute Therapies 14 % 1 % 15 % Kidney Care 3 % 1 % 4 % Other (47 )% 0 % (47 )% Total - Continuing Operations 2 % 1 % 3 % *Totals may not add across due to rounding Constant currency sales growth is a non-GAAP measure. For more information on the company’s use of non-GAAP financial measures, please see the Non-GAAP Financial Measures section of this press release. BAXTER INTERNATIONAL INC. Reconciliation of Non-GAAP Financial Measures Projected Second Quarter and Full Year 2024 U.S. GAAP Sales Growth to Projected Constant Currency Sales Growth and Projected Second Quarter and Full Year 2024 Adjusted Earnings Per Share (unaudited) Sales Growth Guidance Q2 2024* FY 2024* Sales growth - U.S. GAAP ~1% ~2% Foreign Exchange > 100 bps ~ 50 bps Sales growth - Constant currency 2% - 3% 2% - 3% Adjusted Earnings Per Share Guidance Q2 2024 FY 2024* Adjusted diluted EPS $0.65 - $0.67 $2.88 - $2.98 *Totals may not foot due to rounding Baxter calculates forward-looking non-GAAP financial measures based on forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking adjusted diluted EPS guidance excludes potential charges or gains that would be reflected as non-GAAP adjustments to earnings. Baxter provides forward-looking adjusted diluted EPS guidance because it believes that this measure provides useful information for the reasons noted in the accompanying release. Baxter has not provided reconciliations of forward-looking adjusted EPS guidance to forward-looking GAAP EPS guidance because the company is unable to predict with reasonable certainty the impact of legal proceedings, future business optimization actions, separation-related costs, integration-related costs, asset impairments and unusual gains and losses, and the related amounts are unavailable without unreasonable efforts (as specified in the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K). In addition, Baxter believes that such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

Five new launches reinforce Baxter’s focus on differentiated products and enhance the company’s Pharmaceuticals portfolio in critical therapeutic areas Products feature ready-to-use formulations to help support patient safety and offer added convenience for healthcare professionals DEERFIELD, Ill.--(BUSINESS WIRE)-- Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S. “These launches demonstrate Baxter’s focus on differentiated products that address unmet patient needs in key therapeutic areas, including anti-infective and anti-hypotensive medications,” said Alok Sonig, executive vice president and group president, Pharmaceuticals, at Baxter. “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.” Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following. For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below. Norepinephrine Bitartrate in 5% Dextrose Injection in a new 16 mg/250 mL strength, which is indicated to raise blood pressure in adult patients with severe, acute hypotension. Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths. Vasopressin in 0.9% Sodium Chloride Injection, the first and only FDA-approved ready-to-use Vasopressin in a flexible container. Vasopressin uses Baxter’s proprietary sterile, closed system container, which is collapsible and does not require a vented intravenous set.1 Manufactured closed drug-delivery systems decrease the need for manual admixture and reduce the possibility of contamination.2 Vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Baxter offers Vasopressin in 20 units/100 mL and 40 units/100 mL strengths. Vancomycin Injection, USP in 5% Dextrose in new 1.25 g/250 mL and 1.5 g/300 mL strengths. These launches are Baxter’s first frozen ready-to-use offerings in 250 mL and 300 mL volumes. Vancomycin is indicated for serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths. Ropivacaine Hydrochloride Injection, USP in a ready-to-use, single-dose infusion bag. Ropivacaine is indicated in adults to produce local or regional anesthesia for surgery and for acute pain management. Baxter offers Ropivacaine in 200 mg/100 mL and 400 mg/200 mL strengths. Regadenoson Injection pre-filled syringe, a coronary vasodilator that is commonly used in pharmacologic stress testing. Baxter offers Regadenoson in a 0.4 mg/5 mL strength. Ready-to-use formats of standard concentrations of commonly prescribed drugs may offer operational efficiencies for healthcare providers. Compounding a drug for patient use is a multi-step, manual process that requires oversight by pharmacy staff. A ready-to-use product can simplify the preparation process and support patient safety by reducing the chance of contamination2 and avoiding potential errors that may occur when medications are compounded.3 These newly launched products are now available for use in the U.S. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit and follow us on X/Twitter, LinkedIn and Facebook. Norepinephrine Bitartrate in 5% Dextrose Injection Indications Norepinephrine Bitartrate in Dextrose Injection is indicated to raise blood pressure in adult patients with severe, acute hypotension. Important Risk Information Contraindications: None. Tissue Ischemia: Administration of Norepinephrine Bitartrate in Dextrose Injection to patients who are hypotensive from hypovolemia can result in severe peripheral and visceral vasoconstriction, decreased renal perfusion and reduced urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow despite “normal” blood pressure. Address hypovolemia prior to initiating Norepinephrine Bitartrate in Dextrose Injection. Avoid use in patients with mesenteric or peripheral vascular thrombosis, as this may increase ischemia and extend the area of infarction. Gangrene of the extremities has occurred in patients with occlusive or thrombotic vascular disease or who received prolonged or high dose infusions. Monitor for changes to the skin of the extremities in susceptible patients. Extravasation of Norepinephrine Bitartrate in Dextrose Injection may cause necrosis and sloughing of surrounding tissue. To reduce the risk of extravasation, infuse into a large vein, check the infusion site frequently for free flow, and monitor for signs of extravasation. Avoid administration into the veins in the leg in elderly patients. Emergency Treatment of Extravasation: Infiltrate the ischemic area as soon as possible, using a syringe with a fine hypodermic needle with 5 to 10 mg of phentolamine mesylate in 10 to 15 mL of 0.9% Sodium Chloride Injection in adults. Hypotension after Abrupt Discontinuation: Sudden cessation of the infusion rate may result in marked hypotension. When discontinuing the infusion, gradually reduce the infusion rate while expanding blood volume with intravenous fluids. Cardiac Arrhythmias: Norepinephrine Bitartrate in Dextrose Injection elevates intracellular calcium concentrations and may cause arrhythmias, particularly in the setting of hypoxia or hypercarbia. Perform continuous cardiac monitoring of patients with arrhythmias. Elderly Patients: May be at a greater risk of developing adverse reactions. Adverse Reactions: Most common adverse reactions are hypertension and bradycardia. Drug Interactions: Co-administration of Norepinephrine Bitartrate in Dextrose Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e.g., linezolid) or with tricyclic antidepressants can cause severe, prolonged hypertension. Anti-diabetics: Norepinephrine Bitartrate in Dextrose Injection can decrease insulin sensitivity and raise blood glucose. Concomitant use of Norepinephrine Bitartrate in Dextrose Injection with halogenated anesthetics may lead to ventricular tachycardia or ventricular fibrillation. Monitor cardiac rhythm in patients receiving concomitant halogenated anesthetics. Please see accompanying full Prescribing Information for Norepinephrine Bitartrate in 5% Dextrose Injection. Vasopressin in 0.9% Sodium Chloride Injection Indications Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Important Risk Information Contraindications: Vasopressin in Sodium Chloride Injection is contraindicated in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin. Worsening Cardiac Function: A decrease in cardiac index may be observed with the use of vasopressin. Reversible Diabetes Insipidus: Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation. Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts. Adverse Reactions: The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital). Drug Interactions: Pressor effects of catecholamines and Vasopressin in Sodium Chloride Injection are expected to be additive. Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. Co-administration of ganglionic blockers or drugs causing SIADH (syndrome of inappropriate antidiuretic hormone secretion) may increase the pressor response. Co-administration of drugs causing diabetes insipidus may decrease the pressor response. Pregnancy: May induce tonic uterine contractions that could threaten the continuation of pregnancy. Please see accompanying full Prescribing Information for Vasopressin in 0.9% Sodium Chloride Injection. Vancomycin Injection, USP in 5% Dextrose Indications Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is effective in the treatment of: Infective Endocarditis (staphylococcal endocarditis; endocarditis caused by Streptococcus viridans or S. bovis, alone or in combination with an aminoglycoside; endocarditis caused by enterococci (e.g., E. faecalis), only in combination with an aminoglycoside; diphtheroid endocarditis; early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids in combination with either rifampin, an aminoglycoside, or both) Septicemia Skin and Skin Structure Infections Bone Infections Lower Respiratory Tract Infections To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Important Risk Information Contraindications: Vancomycin is contraindicated in patients with known hypersensitivity to this antibiotic. Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products. Infusion Reactions: Rapid bolus administration (e.g., over several minutes) may be associated with exaggerated hypotension, including shock, and, rarely, cardiac arrest. During or soon after rapid infusion of vancomycin, patients may develop anaphylactoid reactions, including hypotension, wheezing, dyspnea, urticaria, or pruritus. Rapid infusion may also cause flushing of the upper body (“vancomycin infusion reaction”) or pain and muscle spasm of the chest and back. Vancomycin should be administered over a period of not less than 60 minutes. Stopping the infusion usually results in prompt cessation of these reactions. Nephrotoxicity: Systemic vancomycin exposure may result in acute kidney injury (AKI). The risk of AKI increases as systemic exposure/serum levels increase. Monitor renal function in all patients; especially with underlying renal impairment, with co-morbidities, and receiving concomitant therapy with a known nephrotoxic drug. Ototoxicity: It may be transient or permanent. It has been reported mostly in patients who have been given excessive doses, who have an underlying hearing loss, or who are receiving concomitant therapy with another ototoxic agent, such as an aminoglycoside. Vancomycin should be used with caution in patients with renal insufficiency. Severe Dermatologic Reactions: Toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), and linear IgA bullous dermatosis (LABD) have been reported. Cutaneous signs or symptoms reported include skin rashes, mucosal lesions, and blisters. Discontinue vancomycin Injection at the first appearance of signs and symptoms of TEN, SJS, DRESS, AGEP, or LABD. Dosage of vancomycin must be adjusted for patients with renal dysfunction. Clostridioides difficile associated diarrhea (CDAD): May range in severity from mild diarrhea to fatal colitis. CDAD must be considered in all patients who present with diarrhea following antibiotic use. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. Hemorrhagic Occlusive Retinal Vasculitis: Including permanent loss of vision, occurred in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery. The safety and efficacy of vancomycin administered by the intracameral or the intravitreal route have not been established. Adverse Reactions: Not already mentioned above, patients have been reported to have neutropenia, phlebitis, drug fever, nausea, chills, and vasculitis in association with administration of vancomycin. Drug Interactions: Anesthetic Agents: Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions. Monitor renal function in patients receiving vancomycin and concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin. Please see accompanying full Prescribing Information for Vancomycin Injection, USP. Ropivacaine Hydrochloride Injection, USP Indications Ropivacaine Hydrochloride Injection is an amide local anesthetic indicated in adults for the production of local or regional anesthesia for surgery and for acute pain management. Surgical Anesthesia: epidural block for surgery including cesarean section; major nerve block; local infiltration. Acute Pain Management: epidural continuous infusion or intermittent bolus, e.g., postoperative or labor; local infiltration. Important Risk Information Contraindications: Ropivacaine Hydrochloride Injection is contraindicated in patients with a known hypersensitivity to ropivacaine or to any local anesthetic agent of the amide type. General Warning: Delay in proper management of dose-related toxicity, underventilation, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest and, possibly, death. The safe and effective use of local anesthetics depends on proper dosage, correct technique, adequate precautions, and readiness for emergencies. It is essential that aspiration for blood, or cerebrospinal fluid (where applicable), be done prior to injecting any local anesthetic, both the original dose and all subsequent doses, to avoid intravascular or subarachnoid injection. Unintended Intravenous Injection: In performing Ropivacaine Hydrochloride Injection blocks, unintended intravenous injection is possible and may result in cardiac arrhythmia or cardiac arrest. Ropivacaine hydrochloride injection should be administered in incremental doses. It is not recommended for emergency situations, where a fast onset of surgical anesthesia is necessary. Intra-Articular Infusions and Risk of Chondrolysis: Intra-articular infusions of local anesthetics may cause chondrolysis. Ropivacaine Hydrochloride Injection is not approved for this use. Risk of Methemoglobinemia: Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure. Immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue ropivacaine hydrochloride injection and any other oxidizing agents. Central Nervous System Toxicity: Careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness should be performed after each local anesthetic injection. Hepatic Disease: Because amide-type local anesthetics such as ropivacaine are metabolized by the liver, these drugs, especially repeat doses, should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease are at a greater risk of developing toxic plasma concentrations. Adverse Reactions: Most common adverse reactions (incidence ≥ 5%) are hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain. Drug Interactions: Agents structurally related to amide-type local anesthetics: Concurrent use may cause additive effects. Please see accompanying full Prescribing Information for Ropivacaine Hydrochloride Injection, USP. Regadenoson Injection Indications Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. Important Risk Information Contraindications: Do not administer regadenoson injection to patients with: Second- or third-degree AV block, or Sinus node dysfunction, unless these patients have a functioning artificial pacemaker. Myocardial Ischemia: Fatal cardiac events have occurred. Avoid use in patients with symptoms or signs of acute myocardial ischemia, for example unstable angina or cardiovascular instability, who may be at greater risk. Cardiac resuscitation equipment and trained staff should be available before administration. Sinoatrial (SA) and Atrioventricular (AV) Nodal Block: Adenosine receptor agonists, including regadenoson injection, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia. Atrial Fibrillation/Atrial Flutter: New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter have been reported. Hypersensitivity, Including Anaphylaxis: Anaphylaxis, angioedema, cardiac or respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria and rashes have occurred. Have personnel and resuscitative equipment immediately available. Hypotension: Adenosine receptor agonists, including regadenoson injection, induce vasodilation and hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, stenotic valvular heart disease, pericarditis or pericardial effusions, stenotic carotid artery disease with cerebrovascular insufficiency, or hypovolemia. Hypertension: Adenosine receptor agonists, including regadenoson injection, may induce clinically significant increases in blood pressure particularly in patients with a history of hypertension and when the MPI includes low level exercise. Bronchoconstriction: Adenosine receptor agonists, including regadenoson injection, may induce dyspnea, bronchoconstriction and respiratory compromise, especially in patients with chronic obstructive pulmonary disease (COPD) or asthma. Resuscitative measures should be available. Seizure: Regadenoson injection may lower the seizure threshold. New onset or recurrence of convulsive seizures has occurred. Some seizures are prolonged and require urgent anticonvulsive management. Methylxanthine use is not recommended in patients who experience a seizure in association with regadenoson injection. Cerebrovascular Accident (Stroke): Hemorrhagic and ischemic cerebrovascular accidents have occurred. Adverse Reactions: The most common (incidence ≥ 5%) adverse reactions to regadenoson injection are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. Drug Interactions: Methylxanthines, e.g., caffeine, aminophylline and theophylline, interfere with the activity of regadenoson injection. Aminophylline may be used to attenuate severe and/or persistent adverse reactions to regadenoson injection. Dipyridamole may increase the activity of regadenoson injection. When possible, withhold dipyridamole for at least two days prior to regadenoson injection administration. Please see accompanying full Prescribing Information for Regadenoson Injection. This release includes forward-looking statements concerning Norepinephrine Bitartrate in 5% Dextrose Injection, Vasopressin in 0.9% Sodium Chloride Injection, Vancomycin Injection, USP in 5% Dextrose, Ropivacaine Hydrochloride Injection, USP and Regadenoson Injection pre-filled syringe, including potential benefits associated with the use of these products. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance for new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements. Baxter is a registered trademark of Baxter International Inc. 1 Baxter data on > 2 Mercaldi CJ, Lanes S, Bradt J. Comparative risk of bloodstream infection in hospitalized patients receiving intravenous medication by open, point-of-care, or closed delivery systems. Am J Health-Syst Pharm. 2013;70:957-965. 3 Billstein-Leber M, Carrillo CJD, Cassano AT, Moline K, Robertson JJ. ASHP Guidelines on Preventing Medication Errors in Hospitals. Am J Health Syst Pharm. 2018;75(19):1493-1517. US-PH57-240005 (v1.0) 04/2024 View source version on businesswire.com: Contacts Media Contact Andrea Johnson, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3020 Source: Baxter International Inc. View this news release online at: